External Advisory Board
The MARC has assembled a group of distinguished researchers in addictions science, neurobiology, and neuroimmunology to serve as our external advisory board (EAB). The group meets periodically with our investigators, reviews progress reports, and helps evaluate our pilot-project applications. In addition, EAB members may be asked to advise individual members of the MARC as specific issues arise.
Martin Paulus, M.D.
University of California at San Diego
Dr. Paulus' work focuses on how decision-making dysfunctions contribute to the transition from casual use of drugs to dependence and how these dysfunctions contribute to relapse in individuals with stimulant dependence.
Bryan Yamamoto, Ph.D.
University of Toledo
Dr. Yamamoto's primary research interests lie in neuropharmacology, neurodegeneration, and the neurotoxicity of the amphetamines. The overall hypothesis is that the amphetamines, through the enhanced release of dopamine and glutamate, promote excitotoxicity, free-radical mediated oxidative stress, and produce a compromised bioenergetic state that damage dopamine and 5HT neurons.
Abraham Palmer, Ph.D.
Univ. of California at San Diego, La Jolla CA
Dr. Palmer's research examines the relationship between genes and behavior. By identifying genes that influence behavior, they hope to obtain fundamental mechanistic insights into the molecular basis of both health and disease.
Stephen J. Kohut, Ph.D.
McLean Hospital, Harvard Medical School, Boston MA
Dr. Kohut's research uses cutting-edge neuroimaging methodologies and animal models to understand the neural consequences of drug seeking behavior, particularly psychostimulants.
Todd Korthuis, M.D., M.P.H.
Associate Professor of Medicine, OHSU
Dr. Korthuis is Board certified in addiction medicine and infectious disease. He is an authority on MA use in adults with co-morbid HIV and MA use disorder, and leads the Addiction Medicine Residency Program at OHSU.